INT71633

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1997
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 25
Total Number 26
Disease Relevance 10.50
Pain Relevance 10.69

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SLC6A3) cell death (SLC6A3) aging (SLC6A3)
plasma membrane (SLC6A3) transmembrane transport (SLC6A3) cytoplasm (SLC6A3)
Anatomy Link Frequency
striatum 7
brain 2
cleft 1
SLC6A3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 1006 100.00 Very High Very High Very High
positron emission tomography 485 100.00 Very High Very High Very High
imagery 257 100.00 Very High Very High Very High
isoflurane 14 99.78 Very High Very High Very High
Potency 2 99.62 Very High Very High Very High
methadone 21 99.54 Very High Very High Very High
cocaine 34 99.44 Very High Very High Very High
Central nervous system 2 97.84 Very High Very High Very High
sSRI 38 97.48 Very High Very High Very High
anesthesia 12 96.44 Very High Very High Very High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 479 99.20 Very High Very High Very High
Disease 677 98.84 Very High Very High Very High
Psychosis 68 97.12 Very High Very High Very High
Opiate Addiction 10 97.12 Very High Very High Very High
Parkinsonian Disorders 390 97.00 Very High Very High Very High
Cognitive Disorder 55 94.00 High High
Targeted Disruption 6 89.28 High High
Recurrence 3 87.96 High High
Liver Disease 121 87.64 High High
Brain Disease 11 83.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, it is not understood whether methadone maintenance treatment impairs the dopamine transporter in the striatum.
Spec (whether) Negative_regulation (impairs) of dopamine transporter in striatum associated with dopamine and methadone
1) Confidence 0.59 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17977528 Disease Relevance 0.38 Pain Relevance 0.71
The addictive and euphorogenic properties of cocaine are thought to result from inhibition of the dopamine transporter (DAT).
Negative_regulation (inhibition) of DAT associated with dopamine and cocaine
2) Confidence 0.57 Published 1997 Journal Drug Alcohol Depend Section Abstract Doc Link 9330920 Disease Relevance 0 Pain Relevance 0.49
The addictive and euphorogenic properties of cocaine are thought to result from inhibition of the dopamine transporter (DAT).
Negative_regulation (inhibition) of dopamine transporter associated with dopamine and cocaine
3) Confidence 0.57 Published 1997 Journal Drug Alcohol Depend Section Abstract Doc Link 9330920 Disease Relevance 0 Pain Relevance 0.49
Isoflurane treatment for 30 min resulted in a highly significant decrease in the amount of h-DAT on the cell surface (21 +/- 15% of control; P < 0.01) (mean +/- SD; n = 4).
Negative_regulation (decrease) of h-DAT associated with isoflurane
4) Confidence 0.51 Published 2004 Journal Synapse Section Abstract Doc Link 15170819 Disease Relevance 0 Pain Relevance 0.47
In PD patients, SPECT and PET studies have shown a progressive loss of DAT and VMAT2 and reduced dopa decarboxylase activity using [18F]-fluoro-dopa PET (Table 2).
Negative_regulation (loss) of DAT associated with positron emission tomography and disease
5) Confidence 0.44 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.72 Pain Relevance 0.50
This transient increase is most likely due to acute inhibition of DAT, which produces an up-regulation of the protein.
Negative_regulation (inhibition) of DAT
6) Confidence 0.44 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.29 Pain Relevance 0.21
PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
Negative_regulation (imaging) of dopamine transporter associated with dopamine, methadone, opiate addiction and imagery
7) Confidence 0.43 Published 2008 Journal Eur. J. Pharmacol. Section Title Doc Link 17977528 Disease Relevance 0.45 Pain Relevance 0.84
This is so because the abuse potential of MPH is thought to be due to the rapid onset of blockade of the presynaptic dopamine transporter (DAT) in the brain [22].
Negative_regulation (blockade) of DAT in brain associated with dopamine
8) Confidence 0.42 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.42 Pain Relevance 0.08
The exact mechanism of action of stimulants in ADHD is not completely understood, but they are presumed to act through the dopaminergic and adrenergic pathways of the frontostriatal areas in the brain.50,51 Unlike amphetamines which can cause a direct release of dopamine and norepinephrine into the presynaptic cleft, MPH is a mild central nervous system stimulant which acts by blocking the reuptake of dopamine and norepinephrine into the presynaptic cleft by blocking the dopamine transporter protein (DAT).
Negative_regulation (blocking) of DAT in cleft associated with dopamine, central nervous system and attention deficit hyperactivity disorder
9) Confidence 0.41 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.82 Pain Relevance 0.34
It is especially interesting that these studies have also shown that the treatment of ADHD subjects with methyphenidate (Ritalin) decreases the level of the dopamine transporter availability back to normal or below normal levels [54].
Negative_regulation (decreases) of dopamine transporter associated with dopamine and attention deficit hyperactivity disorder
10) Confidence 0.40 Published 2005 Journal Theor Biol Med Model Section Body Doc Link PMC1352384 Disease Relevance 0.58 Pain Relevance 0.33
Also, scientists generally assumed that decreased levels of DAT as measured by PET or SPECT are representative of dopamine terminal loss in the striatum.
Negative_regulation (decreased) of DAT in striatum associated with dopamine and positron emission tomography
11) Confidence 0.38 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.65 Pain Relevance 0.24
However, a firm conclusion that chronic Mn results in the loss of DAT and presumably dopamine neuron terminals in the striatum cannot be made because [11C]-nomifensine is not a selective DAT ligand and because Mn can directly inhibit ligand binding to DAT.
Negative_regulation (loss) of DAT in striatum associated with dopamine
12) Confidence 0.38 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0 Pain Relevance 0.59
Immunohistochemistry experiments suggested but did not prove that isoflurane induced a decrease in cell surface DAT.
Negative_regulation (decrease) of DAT associated with isoflurane
13) Confidence 0.38 Published 2004 Journal Synapse Section Abstract Doc Link 15170819 Disease Relevance 0 Pain Relevance 0.47
In patients with attention deficit hyperactivity disorder (ADHD), stimulant medications (i.e amphetamine and methylphenidate) that block DAT and enhance DA signaling are widely used therapeutically to improve attention [2], [14].
Negative_regulation (block) of DAT associated with dopamine and attention deficit hyperactivity disorder
14) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2699543 Disease Relevance 0.53 Pain Relevance 0.37
Thus, in the study by Kim et al. (2002) and in other SPECT and PET DAT imaging studies, it is possible that the decrease in DAT measured by SPECT may not be representative of DAT loss in the striatum (or, by inference, of dopamine terminal degeneration); rather, the decrease in DAT may reflect the ability of Mn to interfere with radioligand binding to DAT.
Negative_regulation (decrease) of DAT in striatum associated with dopamine, positron emission tomography and imagery
15) Confidence 0.32 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.17 Pain Relevance 0.26
Thus, in the study by Kim et al. (2002) and in other SPECT and PET DAT imaging studies, it is possible that the decrease in DAT measured by SPECT may not be representative of DAT loss in the striatum (or, by inference, of dopamine terminal degeneration); rather, the decrease in DAT may reflect the ability of Mn to interfere with radioligand binding to DAT.
Negative_regulation (loss) of DAT in striatum associated with dopamine, positron emission tomography and imagery
16) Confidence 0.32 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.18 Pain Relevance 0.24
It has been shown to bind to and inhibit the dopamine transporter and norepinephrine transporter at clinically relevant doses, which may be responsible in part for its therapeutic effects [13].
Negative_regulation (inhibit) of dopamine transporter associated with dopamine
17) Confidence 0.31 Published 2010 Journal J Med Toxicol Section Body Doc Link PMC2929436 Disease Relevance 1.22 Pain Relevance 0.48
The inclusion of an imaged control group was essential because one of the longitudinal PET studies included the administration of amphetamine (Guilarte et al. 2006a, 2008), a psychostimulant that depletes dopamine levels and down-regulates DAT.
Negative_regulation (regulates) of DAT associated with dopamine and positron emission tomography
18) Confidence 0.28 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.11 Pain Relevance 0.26
In one study, Kim et al. (2002) observed significant reductions in DAT levels measured by SPECT in two workers who had been occupationally exposed to Mn (Table 2).
Negative_regulation (reductions) of DAT
19) Confidence 0.28 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.73 Pain Relevance 0.35
Thus, in the study by Kim et al. (2002) and in other SPECT and PET DAT imaging studies, it is possible that the decrease in DAT measured by SPECT may not be representative of DAT loss in the striatum (or, by inference, of dopamine terminal degeneration); rather, the decrease in DAT may reflect the ability of Mn to interfere with radioligand binding to DAT.
Negative_regulation (decrease) of DAT in striatum associated with dopamine, positron emission tomography and imagery
20) Confidence 0.28 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.19 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox